Lista de obras - Gerhardt Attard - Dominio Público Uruguay

A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors

artículo científico publicado en 2009

A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies

artículo científico publicado en 2009

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

artículo científico publicado en 2006

A step toward functionally characterized prostate cancer molecular subtypes

artículo científico publicado en 2013

Abiraterone acetate is well tolerated without concomitant use of corticosteroids

artículo científico publicado en 2010

Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer

scientific article published on 23 August 2019

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents

artículo científico publicado en 2013

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.

artículo científico publicado en 2018

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

scientific article published on 01 December 2019

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

artículo científico publicado en 2015

Advances in the management of high-risk localised and metastatic prostate cancer

artículo científico publicado en 2012

All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer.

artículo científico publicado en 2010

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.

artículo científico publicado en 2015

Anti-androgen monotherapy for metastatic prostate cancer

artículo científico publicado en 2014

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

artículo científico publicado en 2009

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

artículo científico publicado en 2013

Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.

artículo científico publicado en 2013

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

artículo científico publicado en 2012

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

artículo científico publicado en 2013

Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

artículo científico publicado en 2011

Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors

artículo científico publicado en 2011

CYP17 inhibition as a hormonal strategy for prostate cancer.

artículo científico publicado en 2008

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses

artículo científico publicado en 2016

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

artículo científico publicado en 2009

Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer.

artículo científico publicado en 2013

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.

artículo científico publicado en 2015

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer

artículo científico publicado en 2015

Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer

scholarly article by Gerhardt Attard et al published February 2012 in The Journal of Clinical Endocrinology and Metabolism

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

artículo científico publicado en 2014

Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

artículo científico publicado en 2014

Complex patterns of ETS gene alteration arise during cancer development in the human prostate

artículo científico publicado en 2007

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer ⬇️

artículo científico publicado en 2015

Diagnostic Gleason score and castration-resistant prostate cancer.

artículo científico publicado en 2016

Evolution of androgen receptor targeted therapy for advanced prostate cancer

artículo científico

Expression profiling of CD133+ and CD133- epithelial cells from human prostate.

artículo científico publicado en 2008

External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone

article

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial

artículo científico publicado en 2015

Familial factors in diabetic nephropathy: an offspring study

artículo científico publicado en 2006

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.

artículo científico publicado en 2013

Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity

article

Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement

artículo científico publicado en 2009

Identifying prognostic signatures in the blood of ovarian cancer patients

artículo científico publicado en 2013

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms

artículo científico publicado en 2013

Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.

artículo científico publicado en 2013

Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

artículo científico publicado en 2015

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.

artículo científico publicado en 2006

Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer

artículo científico publicado en 2008

Integrative clinical genomics of advanced prostate cancer

artículo científico publicado en 2015

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

artículo científico publicado en 2012

Making sense of antisense

artículo científico publicado en 2005

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

artículo científico publicado en 2020

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

artículo científico publicado en 2017

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

artículo científico publicado en 2016

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

artículo científico publicado en 2015

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers

artículo científico publicado en 2012

New prostate cancer drug: Prostate cancer's day in the sun.

artículo científico publicado en 2008

New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway

artículo científico publicado en 2011

Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer

artículo científico publicado en 2012

Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer

artículo científico publicado en 2012

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

artículo científico publicado en 2007

PSA as an intermediate end point in clinical trials

artículo científico publicado en 2009

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients

artículo científico publicado en 2015

PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

artículo científico publicado en 2014

Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase 1b Study

scientific article published on 04 May 2020

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

artículo científico publicado en 2007

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

artículo científico publicado en 2008

Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.

artículo científico publicado en 2015

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

artículo científico publicado en 2009

Plasma AR and abiraterone-resistant prostate cancer.

artículo científico publicado en 2015

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer

artículo científico publicado en 2019

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

artículo científico publicado en 2018

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

artículo científico publicado en 2013

Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

article

Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.

artículo científico publicado en 2014

Prioritizing precision medicine for prostate cancer

scientific article published on 10 April 2015

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

artículo científico publicado en 2012

Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer

scholarly article by C Pezaro et al published April 2015 in Clinical Radiology

Prostate cancer

artículo científico publicado en 2015

Prostate cancer in 2011: redefining the therapeutic landscape for CRPC.

artículo científico

Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer

artículo científico publicado en 2015

Prostate cancers that ‘Wnt’ respond to abiraterone

Prostate epithelial stem cells.

artículo científico publicado en 2005

Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.

artículo científico publicado en 2016

Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer

artículo científico

Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer

artículo científico publicado en 2014

Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'.

artículo científico publicado en 2013

Reporting the Capture Efficiency of a Filter-Based Microdevice: A CTC Is Not a CTC Unless It Is CD45 Negative--Letter

artículo científico publicado en 2011

Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin

artículo científico publicado en 2014

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer

artículo científico publicado en 2013

Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.

artículo científico publicado en 2016

Sequencing of agents in castration-resistant prostate cancer

artículo científico

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

artículo científico publicado en 2015

Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio.

artículo científico publicado en 2014

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse

artículo científico publicado en 2021

Steroid hormone receptors in prostate cancer: a hard habit to break?

artículo científico publicado en 2009

Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone

artículo científico

Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies

artículo científico publicado en 2010

Targeting extra-gonadal androgens in castration-resistant prostate cancer

artículo científico

Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects

artículo científico

The CT flare response of metastatic bone disease in prostate cancer

article

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

artículo científico publicado en 2012

The development of abiraterone acetate for castration-resistant prostate cancer

artículo científico

The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.

artículo científico publicado en 2011

Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients

artículo científico publicado en 2011

Tumor clone dynamics in lethal prostate cancer

artículo científico publicado en 2014

Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone

artículo científico publicado en 2014

Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival

artículo científico publicado en 2011

Update on tubulin-binding agents.

artículo científico publicado en 2006

Utilizing circulating tumor cells: challenges and pitfalls

artículo científico publicado en 2010

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail

artículo científico publicado en 2014

Visceral disease in castration-resistant prostate cancer.

artículo científico publicado en 2013

Lista de obras de Gerhardt Attard

A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors

A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

A step toward functionally characterized prostate cancer molecular subtypes

Abiraterone acetate is well tolerated without concomitant use of corticosteroids

Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Advances in the management of high-risk localised and metastatic prostate cancer

All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer.

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.

Anti-androgen monotherapy for metastatic prostate cancer

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors

CYP17 inhibition as a hormonal strategy for prostate cancer.

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer.

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer

Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

Complex patterns of ETS gene alteration arise during cancer development in the human prostate

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer ⬇️

Diagnostic Gleason score and castration-resistant prostate cancer.

Evolution of androgen receptor targeted therapy for advanced prostate cancer

Expression profiling of CD133+ and CD133- epithelial cells from human prostate.

External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial

Familial factors in diabetic nephropathy: an offspring study

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.

Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity

Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement

Identifying prognostic signatures in the blood of ovarian cancer patients

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms

Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.

Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.

Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer

Integrative clinical genomics of advanced prostate cancer

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Making sense of antisense

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers

New prostate cancer drug: Prostate cancer's day in the sun.

New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway

Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer

Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

PSA as an intermediate end point in clinical trials

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients

PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase 1b Study

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

Plasma AR and abiraterone-resistant prostate cancer.

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.

Prioritizing precision medicine for prostate cancer

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer

Prostate cancer

Prostate cancer in 2011: redefining the therapeutic landscape for CRPC.